Literature DB >> 1976064

Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.

R K Brazzell1, Y H Park, C B Wooldridge, B McCue, R Barker, R Couch, B York.   

Abstract

The pharmacokinetics of three aldose reductase inhibitors (ARIs) were evaluated in various species, including rat, dog, cynomolgus monkey, rhesus monkey, chimpanzee, and man. The three ARIs (AL01567, AL01576, and AL01750) were administered intravenously as a single dose to all species except rat, which was dosed orally with AL01750, and man, who was dosed orally with AL01567 and AL01576. Plasma drug concentrations were measured by HPLC or liquid scintillation spectrometry and various pharmacokinetic parameters (clearance, CL; Vd, volume of distribution; and t1/2) were calculated from the data. Overall the pharmacokinetics of the three compounds were quite similar, each being characterized by low CL, intermediate Vd, and long t1/2. For AL01576, mean CL ranged from 0.21 ml/min/kg in cynomolgus monkey to 0.91 ml/min/kg in dog, mean Vd from 0.66 liter/kg in cynomolgus monkey to 2.4 liters/kg in dog and man and mean t1/2 from 29 hr in dog to 72 hr in man. Mean CL of AL01567 ranged from 0.14 ml/min/kg in man to 1.4 ml/min/kg in dog, mean Vd from 0.45 liter/kg in rat to 3.5 liters/kg in dog and mean t1/2 from 22 hr in rhesus monkey to 63 hr in man. Mean CL of AL01750 ranged from 0.13 ml/min/kg in chimpanzee to 1.3 ml/min/kg in dog, mean Vd from 0.40 liter/kg in rat to 1.8 liters/kg in dog and mean t1/2 from 12 hr in rhesus monkey to 62 hr in chimpanzee. For all three drugs, CL and Vd corrected for body weight were quite similar in all species except dog, whose CL and Vd were two- to fourfold greater than the other animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976064

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.

Authors:  K W Ward; J W Proksch; L M Azzarano; K L Salyers; J E McSurdy-Freed; T M Molnar; M A Levy; B R Smith
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

3.  Metabolism of the aldose reductase inhibitor ALO1567 in man.

Authors:  Y H Park; J E Hudson; R C Barker; B M York; R K Brazzell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

4.  Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.

Authors:  R K Brazzell; P R Mayer; R Dobbs; P J McNamara; R L Teng; J T Slattery
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

5.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors:  R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S).

Authors:  Y H Park; P R Mayer; R Barker; M DuPriest; B W Griffin; G W Williams; B M York; J T Slattery
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

7.  Saturable tissue binding and imirestat pharmacokinetics in rats.

Authors:  J Y Chien; C R Banfield; R K Brazzell; P R Mayer; J T Slattery
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

Review 8.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.